血管紧张素转换酶抑制剂在肾功能不全中的应用
摘要
各类肾脏疾病所致肾功能不全的高血压病人,当采用血管紧张素转换酶抑制剂治疗时,可有效地控制血压,可使肾功能改善,减少蛋白尿,长期应用无严重不良反应,但对单、双侧肾血管性高血压者、血管神经性水肿的病人禁用。
二级参考文献14
-
1The Diabetes Control and Complications Trial/Epidemilogy of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy [ J ]. N Engl J Med, 2000,342 (6) : 381-389.
-
2TURNER RC, MILLNS H, NEIL HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus:United Kingdom prospective diabetes study ( UKPDS: 23 ) [J ].BMJ, 1998,316(7134) :823-828.
-
3CORDONNIER DJ, ZAOUI P, HALIMI S. Role of ACE inhibitors in patients with diabetes mellitus[J ]. Drugs,2001,61 (13) :1883-1892.
-
4LAFFEL LMB, MCGILL JB, GANS DJ. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalburrtinuria[J ]. Am J Med, 1995,99(5) :497-504.
-
5The Euclid Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria [ J ]. Lancet, 1997,349(9068) : 1787-1792.
-
6LEWIS EJ. HUNSICKER LG, BAIN RP, et al. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy[J]. N Engl J Med, 1993,329(20) : 1456-1462.
-
7Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy [ J ]. Lancet, 2000,355 (9200) : 253-259.
-
8UK Prospective Diabetes Study Group. Tight blood pressure control and risk of rnacrovascular and microvascular complication in type 2 diabetes:UKPDS 38[J]. BMJ, 1998,317(7160) :703-713.
-
9PIANSSON L, ZANCHETTI A, CARRUTHERS SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optirnal Treatment (HOT) randomised trial [ J ]. Lancet, 1998, 351(9118) :1755-1762.
-
10HANSSON L, LINDHOLM LH, NISKANEN L, et al. Effect of angiotensin-converting-etazyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial [J ]. Lancet, 1999,353(9153) :611-616.
共引文献6
-
1耿宝琴.血管紧张素转化酶抑制药的进展[J].科技通报,1993,9(5):330-335.
-
2王怀湘.依那普利的临床应用进展[J].现代应用药学,1994,11(4):52-53. 被引量：2
-
3王雅娟,钱之玉,沈祥春.糖尿病并发症防治药物研究进展[J].中国新药杂志,2005,14(6):678-682. 被引量：6
-
4谢伟蓉,曹阳,肖顺汉,刘明华.糖尿病血管病变的药物治疗进展[J].四川生理科学杂志,2008,30(1):35-37. 被引量：4
-
5王宝玉,王爱民,余云彬.胰岛素抵抗的药物干预[J].中国煤炭工业医学杂志,2008,11(5):788-789.
-
6邹德平,许志忠,曹灵,陈秋.蜕皮甾酮对早期糖尿病肾病大鼠的影响[J].中国新药与临床杂志,2010,29(11):842-846. 被引量：1
-
1杨笛.替米沙坦与卡托普利对糖尿病肾病患者肾功能的影响[J].浙江中西医结合杂志,2010,20(6):359-360.
-
2de Silva R.,Loh H.,Rigby A.S.,罗亮.慢性心力衰竭患者以磁共振血管造影检出肾动脉狭窄的流行病学特征、相关因素及预后[J].世界核心医学期刊文摘（心脏病学分册）,2007(12):14-14. 被引量：2
-
3施仲伟.钙拮抗剂是否稳定型心绞痛治疗的一线药物[J].中华心脏与心律电子杂志,2015,3(1):6-9. 被引量：1
-
4裴立凯.卡维地洛对心力衰竭患者心功能和心室重塑的影响[J].现代医药卫生,2009,25(12):1847-1847.
-
5Mayers BD,Meyer TW,朱铁虹.血管紧张素转换酶(ACE)抑制剂对实验性糖尿病性肾小球病变的预防[J].国外医学（内分泌学分册）,1990,10(1):20-22.
-
6吴健,刘王明.氯沙坦及依那普利对高血压左室肥厚患者的作用[J].中华老年心脑血管病杂志,2001,3(5):307-307. 被引量：2
-
7李延辉,那开宪.慢性心力衰竭的器械治疗进展[J].中华临床医药杂志（北京）,2004,5(5):40-42.
-
8杨秀春,宗义君.AT1受体拮抗剂和血管紧张素转换酶抑制剂对冠心病患者血小板聚集和炎性标记物的影响[J].国外医学（心血管疾病分册）,2004,31(6):363-363.
-
9万子杰.血管紧张素转换酶抑制剂可降低肺炎风险[J].心血管病防治知识,2012(11):40-40. 被引量：1
-
10魏彤,韩晓玲.卡维地洛与依那普利联合治疗慢性心力衰竭临床观察[J].临床荟萃,2005,20(15):880-881. 被引量：1
